A recent study reported that the combination of BRAF inhibitors with a HDAC3 inhibitor is dramatically efficacious against various subtypes of melanoma with BRAF mutation (44), suggesting that NCoR/HDAC3 recruitment may contribute to oncogene activation under massive ERK activation in V600E-mutated cells. Here, BRAF is linked to melanoma.